Society management

Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

UTRECHT, Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) — Merus NV (Nasdaq: MRUS) (“Merus”, “the Company”, “we” or “our”), a clinical-stage oncology company developing innovative full-length multispecific antibodies ( Biclonics® and triclonics®), today announced the selection of an abstract for oral presentation in 2022 American Society for Clinical Oncology (ASCO) Annual Meeting, held at Chicago, Ill. on June 3-7, 2022.

The presentation will highlight updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), in NRG1 fusion positive (NRG1+) cancer. Merus is currently recruiting patients for the Phase 1/2 eNRGy trial to evaluate the safety and antitumor activity of Zeno monotherapy in NRG1+ cancer.

Oral presentation:

Title: Efficacy and Safety of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, in Advanced NRG1 (NRG1+) Fusion Cancers
Main author: Alison Schramdoctor, Memorial Sloan Kettering Cancer CenterNY
Abstract #: 105
Session title: Clinical Science Symposium / Bispecifics: Are two better than one?
Session date and time: June 5, 2022, 9:45 a.m. – 11:15 a.m. CT

The summary highlighting the interim clinical data will be available at May 26 to 5:00 p.m. ET and an oral presentation, containing an updated interim analysis of clinical data, will be presented to meeting attendees and via livestream to online-only meeting attendees, during the clinical sciences symposium, Bispecifics: Are Two Better Than One?, session on June 5 from 9:45 a.m.-11:15 a.m. CT. The presentation will be available on the Merus website shortly after the live presentation.

We continue to be encouraged by the ongoing trial, observed clinical activity and safety profile and look forward to sharing an interim clinical data update of the May 26 summary and to ASCO on June 5.

Company Conference Call and Webcast Information
Merus will host a conference call and webcast for investors on Sunday, June 5, 2022 to 6:00 PM CT to discuss updated interim clinical data. A replay will be available after the call ends in the Investors and Media section of our website.

About Zeno
Zeno is an Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Biclonics® which uses the Merus Dock & Block® mechanism to inhibit the neuregulin/HER3 tumor signaling pathway in solid tumors with NRG1 gene fusions (NRG1+). Through its unique mechanism of binding to HER2 and potently blocking the interaction of HER3 with its NRG1 ligand or NRG1 fusion proteins, Zeno has the potential to be particularly effective against NRG1+ cancers. In preclinical studies, Zeno also potently inhibited HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.

Learn more about Docking station and Zeno block® at https://merus.nl/technology/.

About Merus SA
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapies called Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to exhibit many of the same characteristics as conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For more information, please visit the Merus website, http://www.merus.nl and https://twitter.com/MerusNV.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to historical facts should be considered forward-looking statements, including, without limitation, statements regarding the clinical development of zenocutuzumab, future clinical trial results or interim data, clinical activity and safety profile of Zeno in the ongoing eNRGy trial, as well as presentation planned and the call to investors. These forward-looking statements are based on management’s current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements. expressed or implied by the forward-looking statements. statements, including but not limited to the following: our need for additional funding, which may not be available and which may require us to restrict our operations or relinquish rights to our technologies or Biclonics®Triclonics® and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenues; the long and costly process of clinical drug development, the outcome of which is uncertain; the unpredictable nature of our efforts to develop early-stage marketable drugs; potential delays in patient enrollment, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the possibility that such third parties may not perform satisfactorily; impacts of the COVID-19 pandemic; we may not identify suitable Biclonics® or bispecific antibody candidates within our collaborations or our collaborators may not work well within our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors, and our patent applications may be found not to comply with patentability rules and regulations; we may not prevail in any lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or held to be generic or determined to infringe other trademarks.

These and other important factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Security and Exchange Commissionor SECONDon February 28, 2022and our other reports filed with the SECOND, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Although we may choose to update these forward-looking statements at some time in the future, we assume no obligation to do so, even if subsequent events change our views, except as required by applicable law. These forward-looking statements should not be taken to represent our views as of any date subsequent to the date of this press release.

Biclonics®Triclonics® and multiclonic® are registered trademarks of Merus NV

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl

main logo

Source: Merus AG

2022 GlobeNewswire, Inc., source Press Releases